Inhibition of CDCP1 by 8‐isopentenylnaringenin synergizes with EGFR inhibitors in lung cancer treatment
Molecular Oncology · 2023
DOI: 10.1002/1878-0261.13429 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Oncology, 2023. Verfasst von Sze-Ching Wong und 11 weiteren Autor:innen. Beteiligte Einrichtung: Graduate Institute of Biomedical Sciences, China Medical University, Taichung, Taiwan. Hauptthemen laut MEDLINE: ErbB Receptors, Lung Neoplasms. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: China Medical University, Taiwan, Ministry of Health and Welfare, Ministry of Science and Technology.
Abstract (Originalsprache)
CUB domain‐containing protein 1 (CDCP1) contributes to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) resistance by regulating EGFR signaling pathways and is a potential target in lung cancer treatment. This study aims to identify a CDCP1 reducer that synergistically improves TKI treatment. Utilizing a high‐throughput drug screening system, a phytoestrogen 8‐isopentenylnaringenin (8PN) was identified. Upon 8PN treatment, CDCP1 protein levels and malignant features were reduced. 8PN exposure caused the accumulation of lung cancer cells in G0/G1 phase and increased the proportion of senescent cells. In EGFR TKI‐resistant lung cancer cells, the combination of 8PN and TKI synergistically reduced cell malignance, inhibited downstream EGFR pathway signaling, and exerted additive effects on cell death. Moreover, combination therapy effectively reduced tumor growth and enhanced tumor necrosis in tumor xenograft mice models. Mechanistically, 8PN increased interleukin (IL)6 and IL8 expression, induced neutrophil infiltration, and enhanced neutrophil‐mediated cytotoxicity to attenuate lung cancer cell growth. In conclusion, 8PN enhances the anticancer efficacy of EGFR TKI on lung cancer and triggers neutrophil‐dependent necrosis, highlighting the potential to overcome TKI resistance in lung cancer patients who have EGFR mutation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Graduate Institute of Biomedical Sciences, China Medical University, Taichung, Taiwan.
- Chinese Medicine Research Center, China Medical University, Taichung, Taiwan.
- Research Center for Chinese Herbal Medicine, China Medical University, Taichung, Taiwan.
- Department of Medicine, School of Medicine, China Medical University, Taichung, Taiwan.
- Department of Surgery, Organ Transplantation Center, China Medical University Hospital, Taichung, Taiwan.
- Center for Molecular Medicine, China Medical University Hospital, Taichung, Taiwan.
ORCID-Profile: Yuh-Pyng Sher
Förderung
- China Medical University, Taiwan
- Ministry of Health and Welfare
- Ministry of Science and Technology
- National Health Research Institutes
Zitieren
APA
Wong, S. C., Yeh, C. C., Zhang, X. Y., Hsieh, C. Y., Lo, C. C., Kuo, T. T., Lin, C. C., Chao, C. H., Liu, J. P., Chang, L. C., Wang, L. H., & Sher, Y. P. (2023). Inhibition of CDCP1 by 8‐isopentenylnaringenin synergizes with EGFR inhibitors in lung cancer treatment. Molecular Oncology. https://doi.org/10.1002/1878-0261.13429
Vancouver
Wong SC, Yeh CC, Zhang XY, Hsieh CY, Lo CC, Kuo TT, et al. Inhibition of CDCP1 by 8‐isopentenylnaringenin synergizes with EGFR inhibitors in lung cancer treatment. Molecular Oncology. 2023. doi:10.1002/1878-0261.13429
BibTeX
@article{Wong2023,
author = {Wong, Sze-Ching and Yeh, Chun-Chieh and Zhang, Xun-Yu and Hsieh, Chih-Ying and Lo, Chia-Chien and Kuo, Ting-Ting and Lin, Ching-Chan and Chao, Chih-Hua and Liu, Jing-Pei and Chang, Ling-Chu and Wang, Lu-Hai and Sher, Yuh-Pyng},
title = {Inhibition of CDCP1 by 8‐isopentenylnaringenin synergizes with EGFR inhibitors in lung cancer treatment},
journal = {Molecular Oncology},
year = {2023},
doi = {10.1002/1878-0261.13429}
}
EUVIMED